Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 140

1.

Elevated expression of the centromere protein-A(CENP-A)-encoding gene as a prognostic and predictive biomarker in human cancers.

Sun X, Clermont PL, Jiao W, Helgason CD, Gout PW, Wang Y, Qu S.

Int J Cancer. 2016 Aug 15;139(4):899-907. doi: 10.1002/ijc.30133. Epub 2016 Apr 21.

PMID:
27062469
2.

Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer.

Clermont PL, Crea F, Chiang YT, Lin D, Zhang A, Wang JZ, Parolia A, Wu R, Xue H, Wang Y, Ding J, Thu KL, Lam WL, Shah SP, Collins CC, Wang Y, Helgason CD.

Clin Epigenetics. 2016 Feb 12;8:16. doi: 10.1186/s13148-016-0182-9. eCollection 2016.

3.

Integrated analysis of the prostate cancer small-nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progression.

Crea F, Quagliata L, Michael A, Liu HH, Frumento P, Azad AA, Xue H, Pikor L, Watahiki A, Morant R, Eppenberger-Castori S, Wang Y, Parolia A, Lennox KA, Lam WL, Gleave M, Chi KN, Pandha H, Wang Y, Helgason CD.

Mol Oncol. 2016 May;10(5):693-703. doi: 10.1016/j.molonc.2015.12.010. Epub 2015 Dec 22.

4.

DNA methylation at enhancer regions: Novel avenues for epigenetic biomarker development.

Clermont PL, Parolia A, Liu HH, Helgason CD.

Front Biosci (Landmark Ed). 2016 Jan 1;21:430-46.

PMID:
26709784
5.

Polycomb genes are associated with response to imatinib in chronic myeloid leukemia.

Crea F, Di Paolo A, Liu HH, Polillo M, Clermont PL, Guerrini F, Ciabatti E, Ricci F, Baratè C, Fontanelli G, Barsotti S, Morganti R, Danesi R, Wang Y, Petrini M, Galimberti S, Helgason CD.

Epigenomics. 2015 Aug;7(5):757-65. doi: 10.2217/epi.15.35. Epub 2015 Sep 7.

PMID:
26343356
6.

Polycomb-mediated silencing in neuroendocrine prostate cancer.

Clermont PL, Lin D, Crea F, Wu R, Xue H, Wang Y, Thu KL, Lam WL, Collins CC, Wang Y, Helgason CD.

Clin Epigenetics. 2015 Apr 3;7:40. doi: 10.1186/s13148-015-0074-4. eCollection 2015.

7.

The long non-coding RNA PCGEM1 is regulated by androgen receptor activity in vivo.

Parolia A, Crea F, Xue H, Wang Y, Mo F, Ramnarine VR, Liu HH, Lin D, Saidy NR, Clermont PL, Cheng H, Collins C, Wang Y, Helgason CD.

Mol Cancer. 2015 Feb 21;14:46. doi: 10.1186/s12943-015-0314-4.

8.

Genotranscriptomic meta-analysis of the Polycomb gene CBX2 in human cancers: initial evidence of an oncogenic role.

Clermont PL, Sun L, Crea F, Thu KL, Zhang A, Parolia A, Lam WL, Helgason CD.

Br J Cancer. 2014 Oct 14;111(8):1663-72. doi: 10.1038/bjc.2014.474. Epub 2014 Sep 16.

9.

Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer.

Crea F, Watahiki A, Quagliata L, Xue H, Pikor L, Parolia A, Wang Y, Lin D, Lam WL, Farrar WL, Isogai T, Morant R, Castori-Eppenberger S, Chi KN, Wang Y, Helgason CD.

Oncotarget. 2014 Feb 15;5(3):764-74.

10.

The non-coding transcriptome as a dynamic regulator of cancer metastasis.

Crea F, Clermont PL, Parolia A, Wang Y, Helgason CD.

Cancer Metastasis Rev. 2014 Mar;33(1):1-16. doi: 10.1007/s10555-013-9455-3. Review.

11.

Genistein versus ICI 182, 780: an ally or enemy in metastatic progression of prostate cancer.

Nakamura H, Wang Y, Xue H, Romanish MT, Mager DL, Helgason CD, Wang Y.

Prostate. 2013 Dec;73(16):1747-60. doi: 10.1002/pros.22712. Epub 2013 Aug 26.

PMID:
24038102
12.

Mutational analysis of Polycomb genes in solid tumours identifies PHC3 amplification as a possible cancer-driving genetic alteration.

Crea F, Sun L, Pikor L, Frumento P, Lam WL, Helgason CD.

Br J Cancer. 2013 Sep 17;109(6):1699-702. doi: 10.1038/bjc.2013.454. Epub 2013 Aug 13.

13.

Histone modifications, stem cells and prostate cancer.

Crea F, Clermont PL, Mai A, Helgason CD.

Curr Pharm Des. 2014;20(11):1687-97. Review.

PMID:
23888964
14.

Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer.

Watahiki A, Macfarlane RJ, Gleave ME, Crea F, Wang Y, Helgason CD, Chi KN.

Int J Mol Sci. 2013 Apr 10;14(4):7757-70. doi: 10.3390/ijms14047757.

15.

Mind-body medicine for schizophrenia and psychotic disorders: a review of the evidence.

Helgason C, Sarris J.

Clin Schizophr Relat Psychoses. 2013 Oct;7(3):138-48. doi: 10.3371/CSRP.HESA.020813. Review.

PMID:
23428783
16.

A family-based intervention targeting parents of preschool children with overweight and obesity: conceptual framework and study design of LOOPS- Lund overweight and obesity preschool study.

Önnerfält J, Erlandsson LK, Orban K, Broberg M, Helgason C, Thorngren-Jerneck K.

BMC Public Health. 2012 Oct 17;12:879. doi: 10.1186/1471-2458-12-879.

17.

The emerging role of histone lysine demethylases in prostate cancer.

Crea F, Sun L, Mai A, Chiang YT, Farrar WL, Danesi R, Helgason CD.

Mol Cancer. 2012 Aug 6;11:52. doi: 10.1186/1476-4598-11-52. Review.

18.

Blood glucose and stroke.

Helgason CM.

Curr Treat Options Cardiovasc Med. 2012 Jun;14(3):284-7. doi: 10.1007/s11936-012-0178-5.

PMID:
22565397
19.

Integrative Mental Health (IMH): paradigm, research, and clinical practice.

Lake J, Helgason C, Sarris J.

Explore (NY). 2012 Jan-Feb;8(1):50-7. doi: 10.1016/j.explore.2011.10.001. Review.

PMID:
22225934
20.

Paracrine signalling loops in adult human and mouse pancreatic islets: netrins modulate beta cell apoptosis signalling via dependence receptors.

Yang YH, Szabat M, Bragagnini C, Kott K, Helgason CD, Hoffman BG, Johnson JD.

Diabetologia. 2011 Apr;54(4):828-42. doi: 10.1007/s00125-010-2012-5. Epub 2011 Jan 7.

PMID:
21212933
Items per page

Supplemental Content

Loading ...
Write to the Help Desk